November 1980

Aspergillosis in Chronic Granulomatous Disease: Therapeutic Considerations

Author Affiliations

Division of Infectious Disease Department of Internal Medicine; Division of Immunology Department of Pediatrics; Division of Infectious Disease Department of Pediatrics State University of New York Downstate Medical Center 450 Clarkson Ave Brooklyn, NY 11203

Am J Dis Child. 1980;134(11):1092-1094. doi:10.1001/archpedi.1980.02130230070021

Children with chronic granulomatous disease (CGD) are susceptible to a wide variety of catalase-positive microorganisms.1Aspergillus infections are particularly difficult to diagnose and treat. Aspergilli may invade many tissues, including the lung,1,2 thyroid,3 and bone,4 and diagnosis frequently requires culture of surgical specimens. Therapy for aspergillosis in children with CGD by use of amphotericin B alone is frequently suboptimal, and several patients have required granulocyte transfusions in addition to amphotericin B.1,2 The need for potentially synergistic combinations of antimicrobials is particularly keen in children with CGD. We report a case of aspergillosis involving the ribs, lung, and pleura that was successfully treated with the combination of amphotericin B and rifampin.

Method of Susceptibility Testing.—The clinical isolate of A fumigatus was grown on Sabouraud's ager slants for seven days. The method of harvesting and quantitating the inocula of the aspergillus and the control organism Candida

First Page Preview View Large
First page PDF preview
First page PDF preview